Label-free drug interaction screening via Raman microscopy

Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2218826120. doi: 10.1073/pnas.2218826120. Epub 2023 Jul 18.

Abstract

Development of a simple, label-free screening technique capable of precisely and directly sensing interaction-in-solution over a size range from small molecules to large proteins such as antibodies could offer an important tool for researchers and pharmaceutical companies in the field of drug development. In this work, we present a thermostable Raman interaction profiling (TRIP) technique that facilitates low-concentration and low-dose screening of binding between protein and ligand in physiologically relevant conditions. TRIP was applied to eight protein-ligand systems, and produced reproducible high-resolution Raman measurements, which were analyzed by principal component analysis. TRIP was able to resolve time-depending binding between 2,4-dinitrophenol and transthyretin, and analyze biologically relevant SARS-CoV-2 spike-antibody interactions. Mixtures of the spike receptor-binding domain with neutralizing, nonbinding, or binding but nonneutralizing antibodies revealed distinct and reproducible Raman signals. TRIP holds promise for the future developments of high-throughput drug screening and real-time binding measurements between protein and drug.

Keywords: Raman spectroscopy; aqueous Raman sampling; protein–ligand interactions; protein–protein interactions.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19*
  • Drug Evaluation, Preclinical
  • Drug Interactions
  • Humans
  • Ligands
  • Microscopy*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / metabolism

Substances

  • Ligands
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Antibodies, Neutralizing
  • spike protein, SARS-CoV-2